Indivior Plc
Research Indivior Plc (INDV) on Bullrun: valuation model: 5.8% overvalued, market cap USD 4.88B, P/E 20.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINDV
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal5.8% overvalued
- Market capUSD 4.88B
- P/E20.9
- Financial periodFY2025
- RevenueUSD 1.24B
- Revenue growth4.3%
- Net incomeUSD 210.00M
- Free cash flow-USD 93.00M
- Gross margin80.2%
Valuation Snapshot
Bullrun's latest valuation model marks Indivior Plc as 5.8% overvalued; latest market cap is USD 4.88B; P/E is 20.9.
About Indivior Plc
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.
Frequently asked questions
Is Indivior Plc overvalued or undervalued?
Bullrun's valuation model currently marks Indivior Plc as 5.8% overvalued.
What is Indivior Plc's market cap?
Indivior Plc's market capitalization is USD 4.88B.
What is Indivior Plc's P/E ratio?
Indivior Plc's price-to-earnings (P/E) ratio is 20.9.
What does Indivior Plc do?
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.